Annual Revenue
$3.55 M
-$237.18 M-98.52%
September 30, 2024
Summary
- As of February 12, 2025, ARWR annual revenue is $3.55 million, with the most recent change of -$237.18 million (-98.52%) on September 30, 2024.
- During the last 3 years, ARWR annual revenue has fallen by -$134.74 million (-97.43%).
- ARWR annual revenue is now -98.54% below its all-time high of $243.23 million, reached on September 30, 2022.
Performance
ARWR Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Revenue
N/A
September 30, 2024
Summary
- ARWR quarterly revenue is not available.
Performance
ARWR Quarterly Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Related metrics
TTM Revenue
N/A
September 30, 2024
Summary
- ARWR TTM revenue is not available.
Performance
ARWR TTM Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
ARWR Revenue Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -98.5% | - | - |
| 3 y3 years | -97.4% | - | - |
| 5 y5 years | -97.9% | - | - |
ARWR Revenue Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -98.5% | at low | ||||
| 5 y | 5-year | -98.5% | at low | ||||
| alltime | all time | -98.5% | >+9999.0% |
Arrowhead Pharmaceuticals Revenue History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | $3.55 M(-98.5%) | - | - |
| Dec 2023 | - | $3.55 M(-77.9%) | $181.74 M(-24.5%) |
| Sep 2023 | $240.74 M(-1.0%) | $16.10 M(+1.7%) | $240.74 M(-6.0%) |
| Jun 2023 | - | $15.82 M(-89.2%) | $256.21 M(-6.1%) |
| Mar 2023 | - | $146.27 M(+133.9%) | $272.80 M(-2.0%) |
| Dec 2022 | - | $62.55 M(+98.1%) | $278.34 M(+14.4%) |
| Sep 2022 | $243.23 M(+75.9%) | $31.57 M(-2.6%) | $243.23 M(-2.7%) |
| Jun 2022 | - | $32.41 M(-78.6%) | $249.94 M(-5.1%) |
| Mar 2022 | - | $151.81 M(+453.2%) | $263.42 M(+82.4%) |
| Dec 2021 | - | $27.44 M(-28.3%) | $144.42 M(+4.4%) |
| Sep 2021 | $138.29 M(+57.2%) | $38.28 M(-16.6%) | $138.29 M(+28.5%) |
| Jun 2021 | - | $45.89 M(+39.9%) | $107.64 M(+20.8%) |
| Mar 2021 | - | $32.81 M(+54.0%) | $89.12 M(+11.6%) |
| Dec 2020 | - | $21.30 M(+179.1%) | $79.84 M(-9.3%) |
| Sep 2020 | $87.99 M(-47.9%) | $7.63 M(-72.1%) | $87.99 M(-28.8%) |
| Jun 2020 | - | $27.38 M(+16.4%) | $123.65 M(-11.0%) |
| Mar 2020 | - | $23.53 M(-20.1%) | $138.97 M(-15.0%) |
| Dec 2019 | - | $29.45 M(-32.0%) | $163.59 M(-3.1%) |
| Sep 2019 | $168.80 M(+945.7%) | $43.29 M(+1.4%) | $168.80 M(+23.4%) |
| Jun 2019 | - | $42.70 M(-11.3%) | $136.76 M(+44.3%) |
| Mar 2019 | - | $48.15 M(+38.9%) | $94.79 M(+100.4%) |
| Dec 2018 | - | $34.66 M(+207.9%) | $47.29 M(+193.0%) |
| Sep 2018 | $16.14 M(-48.6%) | $11.26 M(+1447.3%) | $16.14 M(+18.7%) |
| Jun 2018 | - | $727.40 K(+11.9%) | $13.60 M(-38.8%) |
| Mar 2018 | - | $650.10 K(-81.5%) | $22.22 M(-27.3%) |
| Dec 2017 | - | $3.51 M(-59.7%) | $30.55 M(-2.7%) |
| Sep 2017 | $31.41 M(>+9900.0%) | $8.71 M(-6.7%) | $31.41 M(+38.2%) |
| Jun 2017 | - | $9.34 M(+4.0%) | $22.73 M(+69.3%) |
| Mar 2017 | - | $8.99 M(+105.8%) | $13.42 M(+199.6%) |
| Dec 2016 | - | $4.37 M(>+9900.0%) | $4.48 M(+2730.1%) |
| Sep 2016 | $158.30 K(-58.6%) | $31.30 K(-21.0%) | $158.30 K(-7.3%) |
| Jun 2016 | - | $39.60 K(-9.4%) | $170.70 K(-33.0%) |
| Mar 2016 | - | $43.70 K(0.0%) | $254.80 K(0.0%) |
| Dec 2015 | - | $43.70 K(0.0%) | $254.80 K(-33.3%) |
| Sep 2015 | $382.00 K(+118.3%) | $43.70 K(-64.7%) | $381.90 K(0.0%) |
| Jun 2015 | - | $123.70 K(+183.1%) | $381.90 K(+26.5%) |
| Mar 2015 | - | $43.70 K(-74.4%) | $301.90 K(0.0%) |
| Dec 2014 | - | $170.80 K(+290.8%) | $301.90 K(+72.7%) |
| Sep 2014 | $175.00 K(-39.7%) | $43.70 K(0.0%) | $174.80 K(0.0%) |
| Jun 2014 | - | $43.70 K(0.0%) | $174.80 K(0.0%) |
| Mar 2014 | - | $43.70 K(0.0%) | $174.80 K(0.0%) |
| Dec 2013 | - | $43.70 K(0.0%) | $174.80 K(-39.7%) |
| Sep 2013 | $290.30 K(+97.6%) | $43.70 K(0.0%) | $290.10 K(0.0%) |
| Jun 2013 | - | $43.70 K(0.0%) | $290.10 K(-1.4%) |
| Mar 2013 | - | $43.70 K(-72.5%) | $294.30 K(+4.4%) |
| Dec 2012 | - | $159.00 K(+263.8%) | $281.90 K(+91.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2012 | $146.90 K(-50.4%) | $43.70 K(-8.8%) | $146.90 K(+42.3%) |
| Jun 2012 | - | $47.90 K(+53.0%) | $103.20 K(+86.6%) |
| Mar 2012 | - | $31.30 K(+30.4%) | $55.30 K(+130.4%) |
| Dec 2011 | - | $24.00 K(-91.9%) | $24.00 K(-99.4%) |
| Sep 2011 | $296.10 K(-92.1%) | - | - |
| Dec 2010 | - | $296.10 K(-92.6%) | $4.29 M(-38.4%) |
| Mar 2010 | - | $3.99 M(+2595.5%) | $6.96 M(+117.2%) |
| Dec 2009 | - | $148.10 K(-21.1%) | $3.20 M(-14.7%) |
| Sep 2009 | $3.76 M(+188.4%) | $187.60 K(-92.9%) | $3.76 M(+7.0%) |
| Jun 2009 | - | $2.63 M(+1017.7%) | $3.51 M(+215.5%) |
| Mar 2009 | - | $235.60 K(-66.4%) | $1.11 M(-30.8%) |
| Dec 2008 | - | $701.70 K(-1273.4%) | $1.61 M(+22.8%) |
| Sep 2008 | $1.30 M(+7.9%) | -$59.80 K(-125.4%) | $1.31 M(-32.8%) |
| Jun 2008 | - | $235.40 K(-67.7%) | $1.95 M(-16.6%) |
| Mar 2008 | - | $729.80 K(+81.1%) | $2.33 M(+45.5%) |
| Dec 2007 | - | $402.90 K(-30.3%) | $1.60 M(+32.3%) |
| Sep 2007 | $1.21 M(+102.9%) | $578.00 K(-7.2%) | $1.21 M(+80.1%) |
| Jun 2007 | - | $622.60 K(+5509.0%) | $672.90 K(+90.1%) |
| Dec 2006 | - | $11.10 K(-71.7%) | $354.00 K(-40.5%) |
| Sep 2006 | $595.50 K(+0.8%) | $39.20 K(-84.1%) | $595.40 K(-22.3%) |
| Jun 2006 | - | $246.20 K(+328.2%) | $766.50 K(+10.5%) |
| Mar 2006 | - | $57.50 K(-77.2%) | $693.60 K(-2.8%) |
| Dec 2005 | - | $252.50 K(+20.1%) | $713.70 K(+20.8%) |
| Sep 2005 | $590.70 K(+200.9%) | $210.30 K(+21.4%) | $590.70 K(+9.5%) |
| Jun 2005 | - | $173.30 K(+123.3%) | $539.50 K(+33.7%) |
| Mar 2005 | - | $77.60 K(-40.1%) | $403.40 K(+23.8%) |
| Dec 2004 | - | $129.50 K(-18.6%) | $325.80 K(+66.0%) |
| Sep 2004 | $196.30 K(+8434.8%) | $159.10 K(+327.7%) | $196.30 K(+427.7%) |
| Jun 2004 | - | $37.20 K(>+9900.0%) | $37.20 K(+1228.6%) |
| Jun 2003 | - | $200.00(-77.8%) | $2800.00(-3.4%) |
| Mar 2003 | - | $900.00(-43.8%) | $2900.00(+11.5%) |
| Dec 2002 | - | $1600.00(+1500.0%) | $2600.00(+8.3%) |
| Sep 2002 | $2300.00(-75.3%) | $100.00(-66.7%) | $2400.00(-20.0%) |
| Jun 2002 | - | $300.00(-50.0%) | $3000.00(-50.0%) |
| Mar 2002 | - | $600.00(-57.1%) | $6000.00(+9.1%) |
| Dec 2001 | - | $1400.00(+100.0%) | $5500.00(-40.9%) |
| Sep 2001 | $9300.00(-62.7%) | $700.00(-78.8%) | $9300.00(-45.3%) |
| Jun 2001 | - | $3300.00(+3200.0%) | $17.00 K(-8.1%) |
| Mar 2001 | - | $100.00(-98.1%) | $18.50 K(-26.0%) |
| Dec 2000 | - | $5200.00(-38.1%) | $25.00 K(+0.8%) |
| Sep 2000 | $24.90 K(-32.7%) | $8400.00(+75.0%) | $24.80 K(+51.2%) |
| Jun 2000 | - | $4800.00(-27.3%) | $16.40 K(+41.4%) |
| Mar 2000 | - | $6600.00(+32.0%) | $11.60 K(+132.0%) |
| Dec 1999 | - | $5000.00 | $5000.00 |
| Sep 1999 | $37.00 K(-38.7%) | - | - |
| Sep 1998 | $60.40 K(-21.1%) | - | - |
| Sep 1997 | $76.60 K | - | - |
FAQ
- What is Arrowhead Pharmaceuticals annual revenue?
- What is the all time high annual revenue for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals annual revenue year-on-year change?
- What is the all time high quarterly revenue for Arrowhead Pharmaceuticals?
- What is the all time high TTM revenue for Arrowhead Pharmaceuticals?
What is Arrowhead Pharmaceuticals annual revenue?
The current annual revenue of ARWR is $3.55 M
What is the all time high annual revenue for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high annual revenue is $243.23 M
What is Arrowhead Pharmaceuticals annual revenue year-on-year change?
Over the past year, ARWR annual revenue has changed by -$237.18 M (-98.52%)
What is the all time high quarterly revenue for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high quarterly revenue is $151.81 M
What is the all time high TTM revenue for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high TTM revenue is $278.34 M